Publication details

Jak používáme v České republice inhibitory tyrozinkinázy (TKI) po stanovení diagnózy u pacientů s NSCLC?

Title in English How tyrosine kinase inhibitors (TKI) are used for diagnosis of non-small cell lung cancer (NSCLC) in the Czech Rebuplic
Authors

SKŘIČKOVÁ Jana CHLOUPKOVÁ Renata BORTLÍČEK Zbyněk HEJDUK Karel BRABEC Petr DUŠEK Ladislav PEŠEK M. KOLEK V. GRYGÁRKOVÁ I. KOUBKOVÁ L. ČERNOVSKÁ M. TOMÍŠKOVÁ Marcela ROUBEC J. HAVEL L. SALAJKA F. HRNČIARIK M. ZEMANOVÁ M. ŠATÁNKOVÁ Monika BENEJOVÁ Andrea SIXTOVÁ D. MAREL M. KREJČÍ J. OPÁLKA P. ČOUPKOVÁ H.

Year of publication 2017
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description Three tyrosine kinase inhibitors are curently available in the Czech Republic to treat NSCLC patients with activating mutations in the EGFR gene. Characteristics (such as age, sex, smoking habit) of Czech patients treated with gefinitib (138), afatinib (102) and erlotinib (40) in the years 2013-2016 were compared. Apart from significantly lower performance status in the afatinib group, no other statistically significant differences were found.

You are running an old browser version. We recommend updating your browser to its latest version.

More info